8-K: Neogen Reports Steep Q4 Net Loss Driven by Goodwill Impairment Amid Market Headwinds

Neogen Corporation announced a significant fourth-quarter net loss of $612.2 million, primarily due to a non-cash goodwill impairment charge, alongside declining revenues and persistent end-market challenges.

Summary

• Fourth-quarter 2025 revenue was $225.5 million, a 4.8% decrease compared to $236.8 million in the prior year, with core revenue declining 2.9%.
• Full-year 2025 revenue was $894.7 million, a 3.2% decrease from $924.2 million in the prior year, with core revenue declining 0.2%.
• Net loss for the fourth quarter was $612.2 million, or $(2.82) per diluted share, primarily due to a non-cash goodwill impairment charge of $597.9 million related to the former 3M Food Safety Division acquisition.
• Net loss for the full year was $1,092.0 million, or $(5.03) per diluted share, driven by non-cash goodwill impairment charges totaling $1,059.3 million.
• Adjusted Net Income for the fourth quarter was $11.3 million, or $0.05 per diluted share, down from $22.4 million, or $0.10 per diluted share, in the prior-year period.
• Adjusted Net Income for the full year was $70.9 million, or $0.33 per diluted share, down from $97.4 million, or $0.45 per diluted share, in the prior year.
• Gross margin in the fourth quarter was 41.2%, a decrease from 47.9% in the prior year, primarily due to transaction and integration costs, sample collection production relocation, elevated inventory adjustments, and lower revenue.
• Fourth-quarter Adjusted EBITDA was $40.6 million, representing an 18.0% margin, compared to $53.0 million and a 22.4% margin in the prior-year period.
• Full-year Adjusted EBITDA was $184.2 million, representing a 20.6% margin, compared to $213.2 million and a 23.1% margin in the prior year.
• Food Safety segment revenue decreased 3.0% in Q4 to $161.8 million, with a 1.3% core revenue decline.
• Animal Safety segment revenue decreased 8.9% in Q4 to $63.6 million, with a 6.7% core revenue decline.
• As of May 31, 2025, the company had $129.0 million in cash and investments and $900.0 million in total outstanding debt, with $150.0 million in committed borrowing headroom.
• The company intends to repay $100 million of debt in the first quarter of fiscal 2026 using proceeds from the Cleaners & Disinfectants divestiture, which closed on July 17, 2025.
• For fiscal year 2026, revenue is anticipated to be in the range of $820 million to $840 million, and Adjusted EBITDA is expected to be $165 million to $175 million.
• Capital expenditures are expected to decline significantly in fiscal year 2026 to approximately $50 million from $105 million in fiscal 2025.

Sentiment

Score: 3

Explanation: The significant net loss driven by goodwill impairment, coupled with declining revenues, lower profitability metrics (Adjusted Net Income, Adjusted EBITDA, Gross Margin), and a cautious outlook for FY26, indicates a negative financial performance. While management expresses optimism about long-term drivers and integration progress, the immediate financial results and market conditions are challenging.

Positives

• Food Safety core revenue grew low-single-digits in the fourth quarter and mid-single digits for the full year, excluding specific challenges in the sample collection product line.
• Core revenue growth was observed in Biosecurity products and the Bacterial & General Sanitation product category, benefiting from strong growth in pathogen detection products.
• Solid growth from new food quality and nutritional analysis products contributed positively to the Indicator Testing, Culture Media & Other product category.
• Modest growth was achieved in the allergens product category within Natural Toxins & Allergens.
• Strong growth in rodent control products was noted within the Animal Safety segment's biosecurity portfolio.
• The global Genomics business experienced sequential improvement, with strong growth in the bovine market, particularly internationally.
• Petrifilm production, a final piece of the integration, continues to progress well.
• The current regulatory backdrop in the US is viewed as favorable for food safety, with key announcements from the USDA.
• Capital expenditures are expected to decline significantly in fiscal year 2026 to approximately $50 million from $105 million in fiscal 2025.
• The company plans to repay $100 million of debt in the first quarter of fiscal 2026, which would reduce its net leverage ratio by approximately 0.4x on a pro forma basis.

Negatives

• Reported a net loss of $612.2 million in Q4 2025 and $1,092.0 million for the full year, primarily due to significant non-cash goodwill impairment charges related to the former 3M Food Safety Division acquisition.
• Revenue decreased by 4.8% in Q4 and 3.2% for the full year, with core revenue also declining.
• Adjusted Net Income and Adjusted EBITDA significantly decreased compared to the prior year, indicating lower operating profitability.
• Gross margin declined to 41.2% in Q4 from 47.9% in the prior year, attributed to transaction and integration costs, relocated production issues, elevated inventory adjustments, and lower revenue.
• Softer end-market conditions, elevated trade uncertainty, and the cumulative effect of inflation on food production continued to impact results.
• Profitability in the fourth quarter was explicitly stated as being below expectations.
• Experienced specific challenges and a decline in sales for the sample collection product line.
• Sales of Petrifilm declined, largely due to comparison against a prior-year quarter with reduced backlog.
• Sales of natural toxin test kits declined within the Natural Toxins & Allergens product category.
• The Animal Safety segment experienced an 8.9% revenue decrease in Q4, driven by declines in needles and syringes, vitamin injectables, and insect control products.
• The Genomics business saw a decline in the companion animal and other markets.
• The fiscal year 2026 revenue outlook reflects an expectation of continued end-market weakness.
• The FY26 Adjusted EBITDA outlook includes estimated negative impacts from sample collection production inefficiencies and tariffs.

Risks

• Continued softer end-market conditions and elevated trade uncertainty.
• Ongoing cumulative effect of inflation on food production.
• Specific challenges in the sample collection product line.
• Transaction and integration related costs, particularly those associated with the relocated production of sample collection products.
• Elevated level of inventory adjustments.
• Risk of further non-cash goodwill impairment charges, especially related to the acquisition of the former 3M Food Safety Division.
• Negative impact of sample collection production inefficiencies.
• Impact of tariffs on operations and profitability.
• Volatility caused by foreign currency translation rates.
• General risks and uncertainties outlined in the company's most recently filed Form 10-K.

Future Outlook

For fiscal year 2026, Neogen anticipates revenue to be in the range of $820 million to $840 million, primarily reflecting the expectation of continued end-market weakness. Adjusted EBITDA is expected to be between $165 million and $175 million, which includes a lower level of inventory write-offs, but also accounts for the estimated negative impact of sample collection production inefficiencies and tariffs. Capital expenditures are projected to significantly decline to approximately $50 million from $105 million in fiscal 2025. This outlook excludes the results of the divested Cleaners & Disinfectants business from its closing date of July 17, 2025, forward.

Management Comments

• "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production."
• "We believe the Food Safety end market can still grow in this environment, but at a rate below what we estimate as its normal historical performance."
• "Although profitability in the fourth quarter was below our expectations, we have multi-pronged improvement actions underway to address the several issues that weighed on our results in the quarter and expect to see a decreasing impact moving forward."
• "As the Company progresses into the later stages of the integration, the final piece, Petrifilm production, continues to progress well."
• "Our core mission — helping to protect the world’s food supply — has never been more relevant and we believe that our long-term growth drivers remain fully intact."
• "The global food system is under increasing pressure to be safer, more transparent and more resilient, and we see the current regulatory backdrop as favorable, particularly in the US, with the USDA having made key announcements this month focused on the priority of food safety."
• "The Neogen team is entirely focused on the road ahead and executing with precision, excited about the positive future we believe is in store for the Company."

Industry Context

The filing highlights that Neogen is operating within a global food system facing increasing pressure for safety, transparency, and resilience, exacerbated by ongoing inflation and trade uncertainty. Despite these broad challenges impacting end-market conditions and food production, the company identifies a favorable regulatory environment, particularly in the US, with recent USDA announcements prioritizing food safety. This suggests a potential tailwind for Neogen's core Food Safety business, positioning the company as a key partner for customers and regulators in enhancing food safety efforts.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing for direct industry comparison.

Stakeholder Impact

• Shareholders: Significant net loss and goodwill impairment could negatively impact shareholder equity and perception. Reduced profitability and revenue decline may lead to lower share price. The planned debt repayment could be viewed positively.
• Employees: Restructuring costs and transformation initiatives mentioned in non-GAAP adjustments could imply workforce adjustments, including severance.
• Customers: Challenges in the sample collection product line and a decline in Petrifilm sales could indicate supply or demand issues affecting customers. The company's continued focus on food safety and innovation aims to benefit customers.
• Creditors: The intention to repay $100 million of debt in Q1 FY26 from divestiture proceeds is positive for creditors, as it will reduce the company's net leverage ratio.

Next Steps

• Continue multi-pronged improvement actions to address issues that weighed on profitability in the fourth quarter.
• Progress into the later stages of integration, specifically focusing on Petrifilm production.
• Repay $100 million of debt in the first quarter of fiscal 2026 using net proceeds from the Cleaners & Disinfectants divestiture.
• Focus on executing with precision to achieve a positive future for the company.
• Host a conference call on July 29, 2025, at 8:00 a.m. Eastern Time to discuss the financial results.

Key Dates

Recommendation

The substantial net loss driven by a significant goodwill impairment charge, coupled with declining revenues and lower profitability across key metrics (Adjusted Net Income, Adjusted EBITDA, Gross Margin), signals considerable operational and financial challenges. The negative outlook for FY2026 revenue, reflecting continued end-market weakness, further reinforces concerns. While management highlights ongoing integration and long-term drivers, the immediate financial performance and the need for "multi-pronged improvement actions" suggest a period of uncertainty and potential underperformance. The goodwill impairment specifically points to a re-evaluation of the value derived from a major acquisition (3M Food Safety Division), which is a red flag for investors. Given these factors, a seasoned investor would likely consider selling to mitigate further downside risk until clear signs of a sustained turnaround emerge.

Keywords

Food Safety, Animal Safety, Diagnostics, Goodwill Impairment, Financial Results, Quarterly Report, SEC Filing, NEOG, NASDAQ, Inflation, Integration Costs, Revenue Decline, Net Loss, Adjusted EBITDA, Petrifilm, Biosecurity, Genomics, Debt Repayment